You are here: Industry Insights > ADCETRIS

News List

Press Release Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymph FirstWordPharma
December 13, 2021
Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile.
NICE backing for Takeda's Adcetris for rare lymphoma pharmatimes
July 14, 2020
Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care Excellence (NICE) as a treatment for untreated systemic anaplastic large cell lymphoma (sALCL), a rare type of lymphoma.
NICE recommends Adcetris (brentuximab vedotin) for treatment of rare lymphoma europeanpharmaceuticalreview
July 14, 2020
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
Takeda gets expanded EC approval for lymphoma drug Adcetris pharmaceutical-business-review
May 19, 2020
Takeda Pharmaceutical has secured expanded approval from the European Commission (EC) for its Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
EU regulators approve Takeda's Adcetris for sALCL pharmatimes
May 15, 2020
European regulators have approved Takeda's Adcetris (brentuximab vedotin) for use in adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
EC expands Takeda’s Adcetris authorisation for Hodgkin lymphoma pharmaceutical-technology
February 14, 2019
The European Commission (EC) has expanded the marketing authorisation of Takeda Pharmaceutical’s Adcetris (brentuximab vedotin) to adults with previously untreated CD30+ Stage IV Hodgkin lymphoma....
Seattle Genetics CEO goes inside its lightning-quick Adcetris nod, courtesy of FDA's real-time pilot fiercepharma
December 05, 2018
Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.
Seattle Genetics CEO goes inside its lightning-quick Adcetris nod, courtesy of FDA's real-time pilot fiercepharma
December 05, 2018
SAN DIEGO—Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.
FDA approves treatment for peripheral T-cell lymphoma europeanpharmaceuticalreview
November 20, 2018
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program…
NICE OKs three new therapies for blood cancer pharmatimes
July 09, 2018
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.

Previous page 1 2 Next page